Abstracts tagged "Epidemiology"

Abstract Number: 0120 • ACR Convergence 2023
Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study
Mucong Li¹, Chaiquan Li², Mengzhuo Cao³, Ke Lu², Chanyuan Wu³, Jiuliang zhao¹, Qian Wang⁴, Xinping Tian¹, Xun Tang², Mengtao Li¹, xiaofeng Zeng⁴ and Pei Gao², ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking University, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is becoming a public health concern because of increasing disease and economic burdens. Epidemiological information on SLE, especially its incidence…
Abstract Number: 0232 • ACR Convergence 2023
Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USA
Susan dosReis¹, Chengchen Zhang¹, Alejandro Amill-Rosario¹, Abree Johnson¹, Haeyoung Lee¹, O’Mareen Spence², Driss Oraichi², Harry Seifert², Valentine Franck³, Susan Gamble² and Huifeng Yun², ¹University of Maryland School of Pharmacy, Baltimore, MD, ²GlaxoSmithKline, Rockville, MD, ³GlaxoSmithKline, Wavre, Belgium
Background/Purpose: In pre‑licensure clinical trials, numerical differences in gout cases between the recombinant zoster vaccine (RZV) and placebo groups have been observed. However, real-world evidence…
Abstract Number: 0543 • ACR Convergence 2023
Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015
Hilde Haukeland¹, Sigrid Reppe Moe¹, Cathrine Brunborg², Antonela Botea³, Nenad Damjanic⁴, Gro Wivestad⁵, Heidi Øvreås⁶, Thea Bøe⁷, Torhild Garen¹, Anniken Orre⁸, Helga Sanner⁹, Øyvind Molberg¹⁰ and Karoline Lerang⁹, ¹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ³Betanien Hospital, Department of Rheumatology, Skien, Norway, ⁴Ostfold Hospital Trust, Department of Rheumatology,, Grålum, Norway, ⁵Hospital of Southern Norway Trust, Division of Rheumatology, Department of Medicine, Kristiansand, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Department of Rheumatology, Lillehammer, Norway, ⁷Vestfold Hospital Trust, Department of Internal Medicine, Tønsberg, Norway, ⁸Vestre Viken Hospital Trust, Department of Rheumatology, Drammen, Norway, ⁹Oslo University Hospital, Department of Rheumatology, Nydalen, Norway, ¹⁰University of Oslo, Institute of Clinical Medicine, Oslo, Norway
Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…
Abstract Number: 0968 • ACR Convergence 2023
Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis
Yumeko Kawano¹, Dana Weisenfeld¹, Qing Liu¹, Mary Jeffway¹, Gregory McDermott¹, Kumar Dahal¹, Jennifer Stuart¹, Jacob Joseph², Tianrun Cai¹, Brittany Weber¹, Tianxi Cai³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Veteran's Affairs Boston Healthcare System, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease including heart failure (HF). HF is a heterogeneous condition that is…
Abstract Number: 1086 • ACR Convergence 2023
Increase Shingrix Vaccination Rate in Patients on JAK Inhibitors: A Quality Improvement Project at the Rheumatology Practice of an Urban Institution
Jin Feng¹ and Kristaq Koci², ¹Icahn School of Medicine at Mount Sinai Morningside and West, New York, NY, ²Icahn School of Medicine at Mount Sinai Morningside and West, Bronx, NY
Background/Purpose: The 2022 ACR guidelines for vaccination strongly recommend recombinant VZV vaccination for all patients > 18 years old who are taking immunosuppressive medication. Studies…
Abstract Number: 1552 • ACR Convergence 2023
Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France
Benjamin Terrier¹, Camille Taillé², Alice Brouquet³, Solenne Tauty³, Francoise Bugnard³, Loic Guillevin⁴, Xavier Puéchal⁵ and Vincent Cottin⁶, ¹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, ³Steve Consultant, Lyon, France, ⁴University Paris Descartes, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁶Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss) belongs to the group of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). There are no recent data on…
Abstract Number: 1820 • ACR Convergence 2023
Statewide Burden of Osteoarthritis in United States Between 1990-2019: A Systematic and Comparative Benchmarking Study
Dhruvkumar Gadhiya¹, Utsav Patel², Hiren Chhayani³, Krushi Shah³, Sneh Patel³, Victor Adedara⁴, Divya Patel³, Hardik Desai⁵ and Swetha Chittipolu⁶, ¹St.Luke's University Health, Anderson Campus, Easton, PA, ²Tulane University, New Orleans, LA, ³G.M.E.R.S. Medical College, Gandhinagar, Gandhinagar, India, ⁴St George’s University SOM, True Blue Greneda, True Blue, Grenada, ⁵Gujarat Adani Institute of Medical Sciences, Bhuj, India., Bhuj, India, ⁶North Mississippi Medical Center, Tupelo, MS
Background/Purpose: Osteoarthritis (OA) is a prevalent and debilitating musculoskeletal condition that has imposed a significant burden on the United States (US) healthcare system. This study…
Abstract Number: 2116 • ACR Convergence 2023
Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study
Hyungjin Kim¹, Yeonghee Eun², Seonyoung Kang³, Jaejoon Lee³, Hoon-Suk Cha³, Jong Ho Cho⁴, Kwangmo Yang⁴, Kyungdo Han⁵ and Dong Wook Shin⁶, ¹Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea, ⁶Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of tuberculosis, particularly in association with the use of biologic disease-modifying anti-rheumatic…
Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 2588 • ACR Convergence 2023
Updated Analyses of Cancer Incidence and Risk Factors in a Large International SLE Cohort
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Murray Urowitz³, John G. Hanly⁴, Caroline Gordon⁵, Michelle Petri⁶, Ellen Ginzler⁷, Daniel Wallace⁸, Sang-Cheol Bae⁹, Juanita Romero-Diaz¹⁰, Mary Anne Dooley¹¹, Christine Peschken¹², David Isenberg¹³, Anisur Rahman¹⁴, Susan Manzi¹⁵, Soren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald van Vollenhoven¹⁸, Ola Nived¹⁹, Diane L. Kamen²⁰, Cynthia Aranow²¹, Jill Buyon²², Guillermo Ruiz-Irastorza²³, Francisco Sanchez-Guerrero²⁴, Dafna Gladman²⁵, Paul R. Fortin²⁶, Jennifer LF Lee²⁷, Luck Lukusa²⁷, Graciela S Alarcón²⁸, Joan Merrill²⁹, Kenneth Kalunian³⁰, Manuel Ramos-Casals³¹, Kristjan Steinsson³², Asad Zoma³³, Anca Askanase³⁴, Munther Khamashta³⁵, Ian Bruce³⁶, Murat Inanç³⁷ and Ann Clarke³⁸, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Northwestern University, Chicago, IL, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷SUNY Downstate Health Sciences University, Brooklyn, NY, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ¹⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹¹Raleigh Neurology Associates, Chapel Hill, NC, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³University College London, London, United Kingdom, ¹⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ¹⁶Rigshospitalet, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹⁹Department of Rheumatology, Institution of Clinical Sciences, Lund University Hospital, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²NYU Grossman School of Medicine, New York, NY, ²³Hospital Universitario Cruces, Barakaldo, Spain, ²⁴University Health Network/Sinai Health system, Toronto, ON, Canada, ²⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ²⁷RI-MUHC, Montreal, QC, Canada, ²⁸Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL, ²⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ³⁰University of California San Diego, La Jolla, CA, ³¹Hospital Clinic, Barcelona, Barcelona, Spain, ³²Landspitali University Hospital, Reykjavik, Iceland, ³³Lanarkshire Centre for Rheumatology and Hairmyres Hospital, East Kilbride, East Kilbride, United Kingdom, ³⁴Columbia University Medical Center, New York, NY, ³⁵GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ³⁶University of Manchester, Manchester, United Kingdom, ³⁷Istanbul University, Istanbul, Turkey, ³⁸University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
Abstract Number: 0124 • ACR Convergence 2023
Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa-Parra¹, Andrew Hanson², Alain Sanchez-Rodriguez³, Jose Meade-Aguilar¹, Cynthia Crowson³ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Patients with SLE experience increased all-cause mortality and have a higher risk of hospitalization than the general population. Recently the classification criteria for SLE…
Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Jie Wei¹, Hyon K. Choi², Nicola Dalbeth³, Xiaoxiao Li⁴, Changjun Li⁵, Chao Zeng⁶, Guanghua Lei⁶ and Yuqing Zhang⁷, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³University of Auckland, Auckland, New Zealand, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁷Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
Abstract Number: 0545 • ACR Convergence 2023
Referral Pattern and Factors Associated with Time to Diagnosis for Lupus in India- multicentric Data from the SLE Special Interest Group (SIG) of the Indian Rheumatology Association (IRA)
Vineeta Shobha¹, Liza Rajasekhar², Shaleni V¹, Arul Rajamurgan³, VijayKR Rao⁴, Subramanian Nallasivan⁵, Dr Yogesh Preet Singh⁶, Avinash Jain⁷, Aradhana Singh⁸, Franciosalgeo George¹, Sourabh Malviya⁹, Deepak Yadav¹⁰, John Mathew¹¹ and Amita Aggarwal¹⁰, ¹St. John's National Academy of Health Science, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³Madras Medical College, Chennai, India, ⁴Divisha Arthritis and Medical Center, Bangalore, India, ⁵Velammal Medical College Hospital, Madurai, India, ⁶Himalayan Institute of Medical Sciences, Dehradun, India, ⁷SMS Medical College, Lucknow, India, ⁸SMSMC&H, Jaipur, India, ⁹Medanta super speciality Hospital, Indore, India, ¹⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹¹Christian Medical College Vellore, Vellore, India
Background/Purpose: Early diagnosis remains an unmet need for SLE patients across the world. Reasons for delay in diagnosis differ in various geographic regions and largely…
Abstract Number: 0972 • ACR Convergence 2023
Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population
Juan Marin¹, Enrique Mazenett¹, Mauricio Sarmiento¹, Rosalbina Perez¹, Claudia Morales¹, Jorge Dominguez¹, Juan Salazar² and Juan-Manuel Anaya³, ¹Coosalud, EPS, Cartagena, Colombia, ²Universidad Nacional, Medellin, Colombia, ³Coosalud, EPS, Bogotá, Colombia
Background/Purpose: An increase in the incidence of autoimmune diseases after COVID-19 has been reported. Since many diseases exhibit population-specific causal effect sizes, we aimed to…
Abstract Number: 1097 • ACR Convergence 2023
Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program
Kelsey Pasch¹, Stephen Lindsey² and Takeda Ferguson³, ¹Louisiana State University -- New Orleans, Baton Rouge, LA, ²LSU Health Science Center, New Orleans, LA, ³LSU Health Science Center School of Public Health, New Orleans, LA
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at increased risk of infection. The Centers for Disease Control and Prevention (CDC) and the ACR strongly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].